Skip to main content

Codon Devices Reportedly Shuts Down

NEW YORK (GenomeWeb News) – Codon Devices is reportedly shutting down its operations, according to an article posted on website of The Boston Globe on Friday.

Calls to Codon were not returned to GenomeWeb Daily News to confirm the report.

The Cambridge, Mass.-based firm markets its synthetic biology products and design services, including its BioFab production platform, to clients in the pharmaceutical, biotechnology, institutional, and bioenergy fields. The BioFab platform combines informatics and proprietary algorithms, automated technology, and biochemical protocols for use in designing and building genetic sequences.

Codon raised $11 million in a round of private financing last year through some well-known life science venture capital firms including Alloy Ventures, Flagship Ventures, Highland Capital Partners, Khosla Ventures, Kleiner Perkins Caufield & Byers, and Tactics II Ventures. The company had raised $20 million in December 2006.

According to the Globe article, Codon's board decided last week to shut down operations after the firm failed to raise additional funds.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.